8-K: Exicure Sells Spherical Nucleic Acid Technology to Flashpoint Therapeutics for $1.5 Million

Exicure has sold its spherical nucleic acid technology, research programs, and clinical assets to Flashpoint Therapeutics for $1.5 million, with potential for future royalties.

Summary

• Exicure, Inc. has entered into an Asset Purchase Agreement with Flashpoint Therapeutics, Inc., selling its spherical nucleic acid-related technology, research and development programs, and clinical assets.
• The gross proceeds from the sale are $1.5 million.
• Exicure will support Flashpoint in developing and licensing the assets and will receive royalties from these activities.
• The transaction was negotiated on an arms-length basis.
• The agreement includes the transfer of intellectual property, contracts, regulatory documentation, and other related assets.
• Flashpoint will assume certain liabilities related to the acquired assets, while Exicure retains all other liabilities.
• The purchase price will be allocated for tax purposes, with Flashpoint preparing the initial allocation.
• Exicure will transfer all acquired assets to Flashpoint within five business days of the closing date.
• Exicure will provide technical support to Flashpoint during the transfer process.
• Flashpoint will have sole control over the development and commercialization of the acquired assets.
• Exicure will receive a royalty on net sales of products developed from the acquired assets, with a minimum royalty rate.
• Exicure will also receive a percentage of gross proceeds from licensing agreements related to the acquired patents, with a minimum licensing fee percentage.
• Flashpoint will manage the prosecution and maintenance of the acquired patents.
• Both parties have agreed to confidentiality obligations regarding the transaction and related information.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Exicure is divesting assets but securing future revenue streams. The deal is structured with a mix of upfront payment and potential future royalties, which is a common practice in the biotech industry. The sentiment is not overly positive as the company is selling core assets.

Positives

• Exicure receives $1.5 million in gross proceeds from the sale of assets.
• Exicure has the potential to earn future royalties from sales of products developed from the acquired assets.
• Exicure has the potential to earn future licensing fees from licensing agreements related to the acquired patents.
• Exicure retains a license to sell existing inventory.
• The agreement includes a minimum royalty floor and a minimum licensing fee floor, providing a safety net for Exicure.
• Exicure is relieved of the financial burden of developing the assets.

Negatives

• Exicure is selling its core technology and research programs.
• Exicure is no longer in control of the development and commercialization of the assets.
• The future royalties and licensing fees are dependent on the success of Flashpoint's development and commercialization efforts.
• The royalty rate and licensing fee percentage are subject to deductions for other licensors.
• The agreement includes a minimum royalty floor and a minimum licensing fee floor, but these are still subject to deductions.

Risks

• The success of the transaction for Exicure is dependent on Flashpoint's ability to successfully develop and commercialize the acquired assets.
• The royalty and licensing fee payments are not guaranteed and are dependent on future sales and licensing agreements.
• There is a risk that Flashpoint may not be able to successfully develop or commercialize the assets.
• There is a risk that the royalty and licensing fee payments may be reduced due to obligations to other licensors.
• There is a risk that the minimum royalty and licensing fee floors may not be sufficient to provide a significant return for Exicure.

Future Outlook

Exicure will receive royalties and licensing fees based on Flashpoint's success in developing and commercializing the acquired assets. Flashpoint will have sole control over the future development and commercialization of the assets.

Industry Context

This transaction reflects a trend in the biotechnology industry where companies focus on core competencies and divest non-core assets. It also highlights the value of spherical nucleic acid technology and its potential for future development.

Comparison to Industry Standards

• The sale of assets for a combination of upfront payment and future royalties is a common structure in the biotech industry.
• The royalty rates and licensing fees are within the typical range for similar transactions.
• The specific terms of the agreement, such as the minimum royalty and licensing fee floors, are tailored to the specific circumstances of the transaction.
• Comparable transactions include the sale of drug candidates or technology platforms by smaller biotech companies to larger pharmaceutical or biotech companies.
• For example, a similar transaction might involve a smaller biotech company selling a preclinical drug candidate to a larger company for an upfront payment, milestone payments, and royalties on future sales.

Management Changes

Stakeholder Impact

• Shareholders may view the sale as a positive step towards financial stability and potential future revenue.
• Employees involved in the divested programs may be impacted by the transfer of assets.
• Customers and partners of Exicure may be affected by the change in ownership of the technology.
• Suppliers and creditors may be impacted by the change in ownership of the assets.

Next Steps

• Exicure will transfer all acquired assets to Flashpoint within five business days of the closing date.
• Flashpoint will submit a letter to the FDA accepting ownership of IND No. 139964.
• Exicure will provide technical support to Flashpoint during the transfer process.
• Flashpoint will prepare an allocation of the purchase price for tax purposes.
• Flashpoint will begin the development and commercialization of the acquired assets.

Key Dates

Keywords

Asset Purchase Agreement, Spherical Nucleic Acid, Technology Transfer, Royalties, Licensing Fees, Intellectual Property, Flashpoint Therapeutics, Exicure, Clinical Assets, Research and Development